PepGen (PEPG) Expected to Release Quarterly Earnings on Thursday

PepGen (NASDAQ:PEPG) is anticipated to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.30) per share for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:00 PM ET.

PepGen (NASDAQ:PEPG) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.05. On average, analysts expect PepGen to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

PepGen Price Performance

PEPG opened at $1.93 on Wednesday. PepGen has a fifty-two week low of $1.01 and a fifty-two week high of $7.80. The firm has a market capitalization of $133.50 million, a price-to-earnings ratio of -1.10 and a beta of 1.89. The company’s 50 day moving average price is $1.81 and its two-hundred day moving average price is $3.17.

Analyst Ratings Changes

PEPG has been the subject of several analyst reports. Weiss Ratings downgraded shares of PepGen from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 2nd. Craig Hallum began coverage on PepGen in a research report on Tuesday, June 16th. They set a “buy” rating and a $11.00 target price for the company. Wall Street Zen upgraded PepGen from a “sell” rating to a “hold” rating in a research report on Sunday, June 7th. Wedbush decreased their price target on PepGen from $5.00 to $4.00 and set an “outperform” rating for the company in a research note on Wednesday, May 13th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of PepGen in a research note on Thursday, May 21st. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $11.50.

Institutional Trading of PepGen

A number of large investors have recently bought and sold shares of PEPG. Rangeley Capital LLC raised its position in shares of PepGen by 133.3% in the 2nd quarter. Rangeley Capital LLC now owns 35,000 shares of the company’s stock worth $39,000 after acquiring an additional 20,000 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of PepGen in the 2nd quarter valued at about $44,000. Burkehill Global Management LP bought a new stake in shares of PepGen during the 3rd quarter valued at about $46,000. Militia Capital Partners LP bought a new stake in shares of PepGen during the 3rd quarter valued at about $72,000. Finally, Qube Research & Technologies Ltd bought a new stake in shares of PepGen during the 2nd quarter valued at about $81,000. 58.01% of the stock is currently owned by institutional investors and hedge funds.

PepGen Company Profile

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).